Replies to post #213817 on Biotech Values

[bladerunner1717]

My thesis is that for a development-stage biotech, the second and third pipeline projects are basically irrelevant. If the first one wins they are good; if they first one fails they are going to tank badly.

Peter,

What about PCYC and MDVN?


Bladerunner